Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 4, 23 | -0.05 Increased by +89.13% | -0.16 Increased by +429.69% |
| Mar 30, 23 | -0.33 Increased by +28.26% | -0.30 Decreased by -33.33% |
| Nov 1, 22 | -0.34 Increased by +17.07% | -0.38 Increased by +27.70% |
| Aug 12, 22 | -0.40 Increased by +4.76% | -0.38 Decreased by -13.85% |
| May 5, 22 | -0.46 Decreased by -15.00% | -0.39 Decreased by -46.02% |
| Mar 30, 22 | -0.46 Decreased by -15.00% | -0.45 Decreased by -4.94% |
| Nov 10, 21 | -0.41 Decreased by -20.59% | -0.46 Increased by +23.63% |
| Jul 29, 21 | -0.42 Increased by +12.50% | -0.43 Increased by +5.41% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by N/A% | -3.77 M Increased by +80.91% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -24.26 M Decreased by -30.39% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -18.59 M Decreased by -19.06% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -21.99 M Decreased by -38.02% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -19.75 M Decreased by -30.02% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -18.60 M Decreased by -22.48% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -15.61 M Decreased by -25.54% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -15.94 M Decreased by -14.71% | Decreased by N/A% Decreased by N/A% |
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.